- Report
- January 2022
- 419 Pages
Global
From €9128EUR$9,500USD£7,836GBP
- Report
- July 2018
- 41 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- February 2018
- 680 Pages
Global
From €21139EUR$22,000USD£18,146GBP
- Drug Pipelines
- February 2018
- 39 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- April 2023
- 156 Pages
Global
€4804EUR$5,000USD£4,124GBP
- Report
- April 2023
- 114 Pages
Global
€3363EUR$3,500USD£2,887GBP
- Report
- April 2023
- 109 Pages
Global
€3363EUR$3,500USD£2,887GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£412GBP
- Report
- January 2019
- 35 Pages
Global
From €961EUR$1,000USD£825GBP
- Report
- March 2023
- 147 Pages
Global
From €5764EUR$5,999USD£4,948GBP
Breo Ellipta is a combination drug used to treat chronic obstructive pulmonary disease (COPD) and asthma. It is a combination of two drugs, fluticasone furoate and vilanterol, which work together to reduce inflammation and open up the airways. Breo Ellipta is a long-acting bronchodilator, meaning it works over a longer period of time than other drugs used to treat respiratory conditions. It is taken once a day, and is available in both an inhaler and a dry powder inhaler.
The Breo Ellipta market is a subset of the larger respiratory drugs market. This market is composed of drugs used to treat a variety of respiratory conditions, including COPD, asthma, and other chronic respiratory diseases. These drugs are used to reduce inflammation, open up airways, and improve breathing.
Some companies in the Breo Ellipta market include GlaxoSmithKline, AstraZeneca, Merck, and Boehringer Ingelheim. Show Less Read more
